QOLP-07. HEALTH-RELATED QUALITY OF LIFE AND SYMPTOM BURDEN IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH BEVACIZUMAB BEYOND PROGRESSION: A PROSPECTIVE TRIAL

BACKGROUND: In BIOMARK trial, patients with newly diagnosed glioblastoma were treated with standard chemoradiotherapy combined with first-line bevacizumab; a subset of patients continued bevacizumab beyond progression (BBP). Neurocognitive function (NCF), symptom burden, and health-related quality o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Tanaka, Shota, Narita, Yoshitaka, Mukasa, Akitake, Nagane, Motoo, Aoki, Tomokazu, Wakabayashi, Toshihiko, Uzuka, Takeo, Nakamura, Hideo, Arakawa, Yoshiki, Suehiro, Satoshi, Nakada, Mitsutoshi, Morita, Satoshi, Kato, Mamoru, Ichimura, Kouichi, Nishikawa, Ryo
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Quality of Life and Palliative Care
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651290/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.732
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares